This prospective nonrandomized study enrolled 16 @entity1 with @entity712 [NYHA (New York Heart Association) III and IV] refractory to a maximal well-tolerated drug therapy. The aims were to evaluate if peritoneal ultrafiltration (PUF) could improve clinical conditions and to determine morbidity secondary to @entity712 ( @entity712 ) and PUF. There were 16 @entity1 (12 male, 4 female) with a mean age of 65.4 years (56-81 years) and follow-up of 15.6 months (4-33 months). Thirteen @entity1 had @entity712 without @entity454 . @entity1 were classified as NYHA class IV (n = 11) or class III (n = 5). One anuric @entity1 had been on previous hemodialysis and switched to APD. PUF was obtained with a 2-L hypertonic dialysis solution, once a day (n = 7) or every 2 days (n = 4). Clinical improvement was obtained for all the @entity1 . Weight decreased from 72.2 to 66.7 kg with a weekly ultrafiltration of 3.74 L (2.2-6.5 L). @entity1372 removal was 79 mmol/day (urinary 43%, peritoneal transport 57%). During the follow-up period, 2 @entity1 received a cardiac transplant since 7 died due to cardiac reasons. Mean hospitalization time was 4.4 and 1.20 per @entity1 per day before and after PUF, respectively. Hospitalization was in keeping with either @entity712 (36%), dialysis complications (16%), or miscellaneous causes (48%). Our experience showed that a functional improvement and a better quality of life were achieved for all these @entity1 with a low rate of hospitalization.

Peritoneal ultrafiltration and refractory XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity712 :: ('MESH:D006333', 'Disease') :: ['congestive heart failure', 'RCHF', 'resistant congestive heart failure'] @entity1372 :: ('MESH:D012964', 'Chemical') :: ['Sodium'] @entity454 :: ('MESH:D007676', 'Disease') :: ['end-stage renal disease']
@entity712 :: (MESH:D006333,Disease) :: ['congestive heart failure']
